Clinical Cancer Research · 2020 · 62 citations · 29 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyVaccinologyAdjuvant ImmunotherapyCancer ImmunotherapyCancer VaccinesImmunotherapy For Genitourinary CancersImmunotherapy For Urologic CancersVaccine EfficacyAdjuvant Androgen Deprivation TherapyCastration-resistant Prostate Cancer TherapyCd8 Positive T CellsDeoxyribonucleic Acid (Dna) VaccineMetastatic Castration-resistant Prostate CancerProstate Cancer ImmunotherapyT-cell Mediated ImmunityVaccine Adjuvant Therapy
Abstract Purpose: Preclinical studies demonstrated that a DNA vaccine (pTVG-AR, MVI-118) encoding the androgen receptor ligand-binding domain (AR LBD) augmented antigen-specific CD8+ T cells, delayed prostate cancer progression and emergence of castration-resistant disease, and prolonged survival of tumor-bearing mice. This vaccine was evaluated in a multicenter phase I trial. Patients and Methods: Patients with metastatic castration-sensitive prostate cancer (mCSPC) who had recently begun androgen deprivation therapy were randomly assigned to receive pTVG-AR on one of two treatment schedules over one year, and with or without GM-CSF as a vaccine adjuvant. Patients were followed for 18 months. Primary objectives were safety and immune response. Secondary objectives included median time to PSA progression, and 18-month PSA-PFS (PPFS). Results: Forty patients were enrolled at three centers. Twenty-seven patients completed treatment and 18 months of follow-up. Eleven patients (28%) had a PSA progression event before the 18-month time point. No grade 3 or 4 adverse events were observed. Of 30 patients with samples available for immune analysis, 14 (47%) developed Th1-type immunity to the AR LBD, as determined by IFNγ and/or granzyme B ELISPOT. Persistent IFNγ immune responses were observed irrespective of GM-CSF adjuvant. Patients who developed T-cell immunity had a significantly prolonged PPFS compared with patients without immunity (HR = 0.01; 95% CI, 0.0–0.21; P = 0.003). Conclusions: pTVG-AR was safe and immunologically active in patients with mCSPC. Association between immunity and PPFS suggests that treatment may delay the time to castration resistance, consistent with preclinical findings, and will be prospectively evaluated in future trials. See related commentary by Shenderov and Antonarakis, p. 5056
29
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17